KTTA

Pasithea Therapeutics Corp

• Benzinga·04/01 21:05

  12 Health Care Stocks Moving In Wednesday's After-Market Session

• Reuters·04/01 11:01

  PASITHEA THERAPEUTICS ANNOUNCES GRANT OF FAST TRACK DESIGNATION BY FDA TO PAS-004 FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) CAUSING SIGNIFICANT MORBIDITY

• TipRanks·03/31 16:30

  Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Pasithea Therapeutics Corp (KTTA) and RenovoRx (RNXT)

• TipRanks·02/20 22:36

  Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

• Reuters·02/20 22:01

  Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule

• Reuters·02/17 12:02

  Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

• TipRanks·01/28 21:58

  Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

• Reuters·01/28 21:19

  Pasithea Therapeutics Corporation Held Special Shareholder Meeting

• TipRanks·01/21 18:00

  Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)

• TipRanks·01/14 11:56

  Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

• Reuters·01/13 12:22

  Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1

• TipRanks·01/13 12:11

  Pasithea Therapeutics provides updated timeline on PAS-004 programs

• Benzinga·01/13 12:08

  Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients

• Reuters·01/13 12:02

  Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer

• Reuters·01/13 12:01

  PASITHEA THERAPEUTICS CORP - TO PRESENT NF1-PN STUDY DATA IN H2 2026